## Important Drug Information

November 19, 2024

# Subject: Release of Baxter's Plasma-Lyte A Injection pH 7.4, Lot # Y449571, with potentially leaking units to prevent drug shortage.

Dear Healthcare Professional,

To address the current drug shortage, Baxter is coordinating with the U.S. Food and Drug Administration to release the lot below with potentially leaking units while under investigation. Leaking bags could be an indicator of non-sterility of the product and therefore should not be used.

The product below was under quality investigation at the time of Hurricane Helene and was stored in our warehouse.

SKU	Lot #	NDC	Product	Expiration Date	Description
			size		
2B2544X	Y449571	0338-	1,000 ml	10/31/2025	PLASMA-LYTE A INJECTION PH 7.4
		0221-04			

### **Description of the Issue**

The defect type that was under investigation for this issue was a potentially leaking unit. The leak would most likely be presented as an obvious defect before handling, and/or would present itself as an obvious defect once pressure is applied. The total amount of leaking units within the lot is low, and the leaking unit would most likely be able to be identified before use.

During the internal review of lot Y449571, the leaks in the primary units were found to be occurring at a rate of 52 Defects Per Million (0.0052%). However, based on historical values of these types of defects the amount of defects introduced into the market could be lower.

### **Recommended Action**

Before using this product, we recommend that you apply pressure to and inspect the bag for leakage or signs of leakage. This could include evidence of past leakage, such as dry residue on the exterior of the bag. Additionally, check to see that solution is clear and free of foreign matter. Discard the solution if solution is not clear.

### **Reporting Complaints and Adverse Events**

Healthcare providers should report quality complaints or adverse events associated with the use of Baxter products:

Complaints: Contacting Baxter Product Surveillance at the Baxter product feedback portal at <a href="https://productfeedback.baxter.com">https://productfeedback.baxter.com</a>, or emailing Baxter at <a href="corporate\_product\_complaints\_round\_lake@baxter.com">corporate\_product\_complaints\_round\_lake@baxter.com</a>, note the lot number(s) and that this product was part of a lot under investigation and affected by Hurricane Helene.

 Adverse Events: Contacting Baxter Patient Safety by calling 866-888-2472 between the hours of 8:00 am and 5:00 pm Central Time, Monday through Friday, or emailing USAT\_Pharmacovigilance@Baxter.com

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail, or by fax:

- Online: Complete and submit the report online at: <u>www.fda.gov/medwatch/report.htm</u>
- **Regular Mail or Fax:** Download form <u>www.accessdata.fda.gov/scripts/medwatch/index.cfm</u> or call 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 800-FDA-0178 (800-332-0178).

If you have any questions about the information contained in this letter or the use of the imported products, please contact Baxter's Medical Information Service at 1-800-933-0303, or Email: medinfo@baxter.com.

This letter is not intended as a complete description of the benefits and risks related to the use of Baxter's Plasma-Lyte A Injection pH 7.4. Please refer to the enclosed full prescribing information.

Sincerely,

lectronically signed by: Simone Diorio Simone Diorio Reason: I approve this Document Date: Nov 19, 2024 12:04 EST

Simone Diorio VP Quality, Medical Products & Therapies Enclosure(s): Full Prescribing Information